Results 121 to 130 of about 18,506 (177)

Incidence of Veno-Occlusive Disease in Patients with Neuroblastoma Treated with Autologous Stem Cell Transplantation After Chemoimmunotherapy with Temozolomide, Irinotecan, and Dinutuximab Beta. [PDF]

Cancers (Basel)
Żebrowska U, Balwierz W, Goździk J, Krasowska-Kwiecień A, Dłużniewska A, Richert-Przygońska M, Czyżewski K, Dębski R, Pogorzała M, Styczyński J, Ussowicz M, Sokół A, Kałwak K, Malinowska I, Romiszewski M, Mańko-Glińska H, Badowska W, Brzeski T, Świerczek-Skwierawska I, Skoczeń S, Wieczorek A.   +20 more
europepmc   +1 more source

Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: Evolving Indications, Conditioning Strategies, and Outcomes. [PDF]

Hematol Rep
Alati C, Botti S, Cogliandro F, Pitea M, Pacilli M, Porto G, Policastro G, Sgarlata A, Mico MC, Loteta B, Giordano L, Santoro G, Germano J, Martino M.   +13 more
europepmc   +1 more source

Long-term survival rates of thalassemia patients following hematopoietic stem cell transplantation: A systematic review and meta-analysis. [PDF]

Hematol Transfus Cell Ther
Adisuhanto M, Prasetya A, Cahyadi A, Oehadian A.   +3 more
europepmc   +1 more source

In vivo T-cell depletion and pharmacokinetic-based busulfan conditioning regimen improve the outcomes in acute myeloid leukemia (AML) in complete remission undergoing to allogeneic stem cell transplantation. [PDF]

Cancer
Bono R, Rotolo C, Sapienza G, Spoto C, Costanza C, Indelicato S, Patti C, Mulè A, Calafiore V, Arrigo G, Santoro A, Di Noto L, Castagna L.   +12 more
europepmc   +1 more source

Clinical Impact of Maximum Plasma Concentration of Busulfan in Pediatric Patients Undergoing Allogenic Hematopoietic Stem Cell Transplantation. [PDF]

Clin Pharmacol Ther
Bae S, Choi JY, Hong KT, Kim BK, Park HJ, Yu KS, Rhee SJ, Kang HJ.   +7 more
europepmc   +1 more source

Toxicity and pharmacokinetics of i.v. busulfan in children before stem cell transplantation

We have introduced a dimethylacetamide-based i.v. formulation of busulfan into pediatrics with a dose intensity [as measured by area under curve (AUC)] comparable to that achieved by oral busulfan while reducing variability. The target AUC was defined at
Oechtering D, Schiltmeyer B, Schwab M, Würthwein G, Fleischack G, Gruhn B, Klingebiel T, Hempel G, Boos J, Mürdter T, Vormoor J   +10 more
core  

Refining busulfan exposure enhances pediatric ALL HSCT outcomes: insights from the International FORUM study. [PDF]

Blood Adv
Ben Hassine K, Gloor Y, Dupanloup I, Uppugunduri CRS, Mlakar V, Gonzales F, Güngör T, Ifversen M, Shaw PJ, Buechner J, Truong TH, Bittencourt H, Teague L, Toporski J, Sedlacek P, Poetschger U, Krajinovic M, Kałwak K, Balduzzi A, Algeri M, Bader P, Peters C, Dalle JH, Ansari M.   +23 more
europepmc   +1 more source

Post-Transplant Cyclophosphamide-Based Related Haploidentical Transplantation for Adult Diamond-Blackfan Anemia: Long-Term Survival and Review. [PDF]

J Hematol
Sakakibara T, Kobayashi S, Ito T, Tachibana M, Ito E.   +4 more
europepmc   +1 more source

From Therapeutic Drug Monitoring to Model-Informed Precision Dosing: A Review of Busulfan Dosing Optimization in Pediatric Hematopoietic Stem Cell Transplantation. [PDF]

Pharmaceutics
Zhang XY, Li Y, Xu J, Fang YJ, Ding XS, Chen F.   +5 more
europepmc   +1 more source

Yes, we can omit TBI for ALL! [PDF]

Blood Adv
Boelens JJ, Dvorak CC.
europepmc   +1 more source